Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.20.1
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jun. 30, 2019
Mar. 31, 2015
Mar. 31, 2020
Mar. 31, 2019
Neupharma [Member] | Additional Sales Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     $ 40,000,000  
Neupharma [Member] | Clinical and Development Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     40,000,000  
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     22,500,000  
Dana-Farber [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maintenance Fee     50,000  
Dana-Farber [Member] | First Commercial Sale Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     27,600,000  
Maximum Potential Milestone Payments     21,500,000  
Dana-Farber [Member] | Additional Sales Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     60,000,000  
Maximum Potential Milestone Payments     60,000,000  
Dana-Farber [Member] | Commercial Sales In Specified Territories [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     21,500,000  
Jubilant Biosys Ltd [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition, Milestone Method, Revenue Recognized     $ 18,000 $ 11,000
Research and Development Cost, Shared Percentage     50.00%  
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     $ 89,000,000  
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     59,500,000  
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     61,700,000  
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     89,000,000  
Maximum Potential Milestone Payments     89,000,000  
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     87,200,000  
Adimab LLC [Member] | Clinical and Development Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     7,100,000  
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     4,800,000  
Collaboration Agreement With TGTX [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Payment of Upfront Fees $ 1,000,000      
Revenue Recognition, Milestone Method, Revenue Recognized     954,000 $ 341,000
Proceeds from Upfront Fees   $ 500,000    
Collaboration Agreement With TGTX [Member] | PD-L1 [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Maximum Potential Milestone Payments     925,000  
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     7,000,000  
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     14,500,000  
Collaboration Agreement With TGTX [Member] | Five Regulatory Approvals And First Commercial Sales [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     19,200,000  
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     8,400,000  
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue Recognition Milestone Method, Payments Due     $ 25,500,000